RHHBY - GenMark Diagnostics may be worth $20-$25/share in takeout Cowen says

GenMark Diagnostics (GNMK) may be worth $20-$25/share in a potential sale, Cowen said, after a Bloomberg report that the company is exploring a sale after receiving approaches. Genmark shares jumping 21%.Cowen has always seen GenMark as an attractive target and the company is the only remaining publicly traded pure-play "syndromic" testing company of scale, according to analyst Doug Schenkel.Potential acquirers could be Hologix (HOLX), Becton, Dickinson (BDX), Thermo Fisher (TMO), and Roche (RHHBY).GNMK remains outperform, PT $23.Recall Jan. 11, GenMark Diagnostics provides preliminary Q4 and FY numbers.

For further details see:

GenMark Diagnostics may be worth $20-$25/share in takeout, Cowen says